BME100 f2014:Group8 L2

From OpenWetWare

Jump to: navigation, search

Results of the Inflammotin Trials

As evidenced by the data in Figure 1, and shown in Figure 2, the Lipopolysaccharide(LPS) had little to no effect on the rats in the in vivo trials. The difference between the inflammation in the rats that were given 10mg of LPS and those who were not given the medicine was negligible.

The clinical trials had a much different result. The 5mg dose more than doubled the average inflammotin levels. As the dose increased, the average inflammotin levels followed exponentially. The 10mg dose raised them almost 20 fold. The 15mg took it to a whole other level raising the inflammotin levels over 200 times that of the control group.


  • Dose vs. Average Inflammotin Levels in Rats

Figure 1 Image:BME-100 lab 2, rat chart.png

Figure 2 Image:BME-100 lab 2, rat graph.png

  • Dose vs. Average Inflammotin Levels in Humans

Figure 3 Image:BME-100 lab 2, human chart.png

Figure 4 Image:BME-100 lab 2, human graph.png


Summary After analyzing the data collected from the experiment, we have concluded that the LPS pills were effective in human trials. Dosage needs to monitored carefully, however, to prevent results that may be harmful to patients. In the rat trials, the LPS doses had little or no effect on their inflammation levels. We did conclude that the 5mg dosage had a positive affect on human patients. This dosage is also less than the target dosage. This is beneficial because it will save the lab money, which was our original goal.

Personal tools